ABSTRACT: Tibial pseudarthrosis associated with Neurofibromatosis type 1 (NF1) is an orthopedic condition with consistently poor clinical outcomes. Using a murine model that features localized double inactivation of the Nf1 gene in an experimental tibial fracture, we tested the effects of recombinant human bone morphogenetic protein-2 (rhBMP-2) and/or the bisphosphonate zoledronic acid (ZA). Tibiae were harvested at 3 weeks for analysis, at which time there was negligible healing in un-treated control fractures (7% union). In contrast, rhBMP-2 and rhBMP-2/ZA groups showed significantly greater union (87% and 93%, p < 0.01 for both). Treatment with rhBMP-2 led to a 12-fold increase in callus bone volume and this was further increased in the rhBMP-2/ZA group. Mechanical testing of the healed rhBMP-2 and rhBMP-2/ZA fractures showed that the latter group had significantly higher mechanical strength and was restored to that of the un-fractured contralateral leg. Co-treatment with rhBMP-2/ZA also reduced fibrous tissue infiltration at the fracture site compared to rhBMP alone (p ¼ 0.068). These data support the future clinical investigation of this combination of anabolic and anti-resorptive agents for the treatment of NF1 pseudarthrosis. 
In children with the autosomal dominant genetic condition NF1, tibial pseudarthrosis is a rare yet challenging orthopedic complication. The natural history of NF1 tibial pseudarthroses typically features a congenital tibial dysplasia that progresses to fracture and subsequent non-union. This condition characteristically requires multiple surgical interventions to facilitate bone healing and prevent residual deformity, however persistent non-union and amputation remain common outcomes. 1, 2, 3 Presently, there is no definitive consensus on the optimal strategy for treating pseudarthrosis in individuals with NF1. 4, 5 The standard of care has traditionally involved the surgical resection of any abnormal hamartomatous tissue along with open reduction and fixation via external frame or intramedullary rod, and bone grafting. 6 Over the past 10 years, preclinical and clinical studies have given important insights into the pathophysiology of deficient NF1 bone healing. One major finding has been the detection of localized double inactivation of the NF1 gene in pseudarthrosis tissue biopsied during surgery. 7, 8 Consequently, a murine model of tibial pseudarthrosis featuring a localized double knockout of Nf1 at the fracture site was generated using Nf1 flox/flox mice and a Cre-expressing adenovirus. 9 This model demonstrates the characteristic pathophysiological features of clinical NF1 pseudarthroses. These include fibrous/hamartomatous tissue at the fracture site, deficient localized bone formation, and enhanced osteoclastogenesis resulting in delayed or non-union. We speculated that this would be a suitable model for preclinical testing of pharmaceutical approaches to enhance deficient NF1 fracture repair.
In 2014, this Nf1 null mouse fracture model was used to test two interventions: Systemic MEK inhibitor PD0325901 and/or local delivery of rhBMP-2. 10 Biologically, the NF1 gene product neurofibromin is a negative regular of Ras and reduced function enhances Ras-MEK-MAPK signaling. 11 In Nf1 null fractures, both targeted inhibition of MEK and local rhBMP-2 administration led to increased callus bone volume. In the case of rhBMP-2 and rhBMP-2 þ PD0325901, union rates were also greatly improved (69% and 80% vs. 8% controls, p < 0.01). 10 However, neither intervention led to a reduction in fibrosis tissue at the fracture site, and the greatest fibrosis was seen with the combination therapy.
Clinically, rhBMPs have been used off-label in NF1 pseudarthrosis to produce improved surgical outcomes. 12, 13 However, anabolic stimulation with rhBMP-2 was anticipated to also produce negative effects on NF1 pseudarthrosis repair, such as enhancing fibrous tissue accumulation and osteoclastic bone resorption.
11 Application of rhBMP-2 has been shown to cause increased osteoclastogenesis even in a non-NF1 setting.
14 While adjunctive rhBMP-2 treatment can yield positive outcomes in some instances, union is still far from guaranteed. Indeed, in a recent clinical case series, rhBMP-2 was more effective in the treatment of non-NF1 pseudarthroses compared to NF1 pseudarthroses. 15 Another approach that has been suggested to improve NF1 pseudarthrosis healing outcomes is rhBMP-2 and bisphosphonate co-treatment. This was previously modeled in the heterozygous Nf1 mouse line, 16 however this system is limited compared to the Nf1 null fracture model in its capacity to recapitulate the genetic and pathophysiology features of the clinical condition. Further evidence for the utility of a rhBMP/ bisphosphonate combination was seen in a clinical case series by Birke et al. 17 in 2011, where primary healing was achieved in 6 of 8 cases of Crawford type IV CPT cases.
In this study, we tested rhBMP-2 and/or the potent third-generation bisphosphonate Zoledronic Acid (ZA) in the Nf1 null fracture model. It was hypothesized that the combined rhBMP-2/ZA treatment would lead to enhanced callus bone volume and biomechanical strength due to synergy between bone anabolic and anti-resorptive therapies. 18 Union and biomechanical strength were defined as the primary outcomes. Additionally, the effects of treatment on local fibrosis were analyzed via tissue histology, as accumulation of fibrotic tissue is viewed as an undesirable outcome.
METHODS

Animal Ethics and Care
The genetically modified Nf1 flox/flox mouse line originally generated by Prof L. Parada. 19 was obtained from the National Cancer Institute mouse repository (Bethesda, MD). Mice were housed in the institutional animal care facility in sterile polypropylene boxes with stainless steel cage lids. Food and water were supplied ad libitum. Animal experiments were approved by the CHW/CMRI institutional Animal Ethics Committee under protocol K319.
Murine Pseudarthrosis Model
10-12-week old female Nf1
flox/flox mice underwent open, tibial mid-shaft fractures with periosteal stripping by expert animal surgeons as described previously. 9, 10 Briefly, mice were anaesthetized prior to surgery using a combination of 35 mg/kg ketamine and 4.5 mg/kg xylazine delivered intraperitoneally (IP). Anesthesia was maintained with inhaled isoflurane gas if required. Fracture were produced manually using a three-point bending method with a handheld modified surgical staple remover. Removal of the periosteum adjacent to the fracture site retards healing and is speculated to improve access to the recombinant Ad-Cre virus. Fractures were internally stabilized using a sterile 0.3 mm diameter stainless steel insect pin to permit healing over 3 weeks.
Local application of purified recombinant Ad-Cre virus to induce a tibial knockout was provided in a variation of the previously published technique where virus was dripped to saturate an absorbable collagen sponge (ACS, Medtronic Australasia) from an rhBMP-2 implant kit. Ad-Cre virus was produced and purified in house as previously described with 1 Â 10 8 infectious units of purified virus applied to the ACS that was implanted at the fracture site at the time of surgery. 10 10 mg lyophilized rhBMP-2 (Medtronic) reconstituted in sterile water was co-administered via the ACS. These values were previously determined empirically. Post-fracture X-rays were obtained following surgery to confirm fracture position and stability and radiographic healing was assessed at 1, 2, and 3 weeks post-surgery using a digital X-ray machine (Faxitron X-ray Corp., Tucson, AZ). X-rays were graded by an experienced observer blinded to treatment group, with both cortices on a lateral x-ray bridged for unions. The bisphosphonate, Zoledronic Acid (Novartis AG, Basel, Switzerland) was delivered systemically as five intraperitoneal injections of 0.02 mg/kg, commencing dosed twice weekly starting 3 days post-fracture. 16 Four groups were tested: (i) vehicle controls (Ad-cre virus only); (ii) ZA only; (iii) rhBMP-2 only; and (iv) rhBMP-2/ZA. A total of n ¼ 15 mice per group were utilized for radiography (union), microCT and mechanical testing outcomes. Additional surgeries were performed for representative histology and analysis of fibrosis (n ¼ 7 vehicle, n ¼ 3 rhBMP-2, n ¼ 4 ZA, n ¼ 4 rhBMP-2/ZA) ( Table 1) .
Micro-Computed Tomography
Fractures were harvested following 3 weeks of healing and scanned without formalin fixation in saline using a SkyScan null fractures lacking pro-anabolic intervention (Vehicle). Treatment with rhBMP-2 and rhBMP-2/ZA augmented radiographic bone formation and union. (B) 3 week union rates by an expert blinded to treatment group showed a significant increase in union rates in rhBMP-2 and rhBMP-2/ZA groups compared to vehicle and ZA only groups (p < 0.01).
rhBMP-2 AND ZA FOR NF1 PSEUDARTHROSIS 931 1174 micro-computed tomography (micro-CT) scanner (Kontich, Belgium). Specimens were scanned with a 0.5 mm aluminum filter, 50 kV X-ray tube voltage, and 800 mA tube electric current. Scanned images were reconstructed using NRecon, software version 1.6.1.7 (SkyScan), and analyzed using CTAnalyser software, version 1.11.8.0 (SkyScan). Bitmaps of scanned images were analyzed by manually selecting the ROI to include the fracture callus and exclude the old bone cortex. Callus bone volume (BV) and total volume (TV) were quantified and used to calculate overall BV/TV ratios.
Mechanical Testing
An Instron 5944 (MA) mechanical testing system performed four-point bending on fractures that were united at 3 weeks (rhBMP-2, n ¼ 10 and rhBMP-2/ZA, n ¼ 11) as well as contralateral tibiae. Only groups where the majority of bones had united were tested. Unfixed samples were stored at À80˚C until testing. Prior to testing, tibiae were thawed, kept moist in 0.9% saline, and then stripped of surrounding muscle. Testing was performed to bone failure on a custom jig with data collected using BlueHill 3 software (Instron, Norwood, MA). Bones were pre-loaded at 0.25 mm/min until 1N after which the loading rate was increased to 0.5 mm/min until catastrophic failure. 20 The maximal load/force, energy to failure up until the point of maximum load, and bone stiffness were all calculated.
Histology
Tibiae were fixed overnight in 4% paraformaldehyde in phosphate buffered saline (pH 7.4) and then stored in 70% ethanol. Prior to embedding, fractures incubated to 30% sucrose/PBS overnight at 4˚C for improved cryo-histology. Fractures were embedded in Tissue-Tek 1 Optimal Cutting
Temperature media (Sakura Finetek, The Netherlands) and 5 mm thick longitudinal frozen sections of un-decalcified bone tissue were cut using a CM1900 cryostat (Leica Microsystems, North Ryde, Australia) on non-fluorescent cryo-tape adhered to slides with chitosan glue. Picrosirius red/alcian blue staining was performed on sections to visualize bone, cartilage and fibrous tissue and quantification was carried out using the Bioquant Image Analysis software.
Statistical Analysis
Statistical analyses were carried out using GraphPad Prism software (La Jolla, CA). For fracture experiments, an n-value of 15 was used for each group, which was calculated to have sufficient statistical power to detect a 50% reduction in nonunion rate in the Nf1 null fracture model. For fracture union rates, a Fisher's Exact Test was employed and ANOVA/ Kruskal-Wallis testing with post hoc multiple comparison testing were used to determine significance for microCT, mechanical testing, and histological quantification. Graphical error bars represent the standard error of the mean and an alpha value of 0.05 was used as the cutoff for statistical significance.
RESULTS
rhBMP-2 Enhances Union Rate in the Nf1
null Fracture Model Blinded radiographic analysis revealed significant improvements with bone union at 3 weeks with both rhBMP-2 and rhBMP-2/ZA versus vehicle and ZA alone ( Ã p < 0.01). The rates for complete union were vehicle (7%), ZA (0%), rhBMP-2 (87%), and rhBMP-2/ ZA (93%) (Fig. 1, Table 2 ). While the union rates were not significantly different between the rhBMP-2 and rhBMP/ZA treatment groups, notably all rhBMP/ZA treated fractures achieved total or partial union.
rhBMP-2 Enhances Callus Bone Volume, Which Is Further Increased by ZA Co-Treatment
Imaging of the fracture calluses by microCT showed that all interventions significantly improved the poor hard callus formation characteristic of the Nf1 null fracture model 9 ( Fig. 2A) . Bone volume, total volume, and BV/TV were quantified from callus ROIs on microCT scans. Measurement of BV showed an effect of all interventions (Fig. 2B) . ZA treatment gave a modest increase in BV (threefold, p < 0.01), and was not associated with increased union rate. In contrast, rhBMP-2 led to a substantive 12-fold increase in hard callus BV (p < 0.01 vs. vehicle and ZA groups) and this was further enhanced in the rhBMP-2/ZA group (p < 0.01 vs. all groups). A similar trend was seen in callus TV (Fig. 2B) . rhBMP-2 AND ZA FOR NF1 PSEUDARTHROSIS While the rhBMP-2 treatments led to increased BV and TV, the total BV/TV values for these groups were reduced. In addition, ZA treatments led to small but significant increases in callus BV/TV.
rhBMP-2/ZA Co-Treatment Yields Improved Bone Strength Compared to rhBMP-2 Alone
A four-point bending test (Fig. 3A) was used to assess the biomechanical properties of maximal load, stiffness, and energy to failure at 3 weeks. Due to the lack of union in the control and ZA groups, only united and partially united fractures of the rhBMP-2 (n ¼ 10) and rhBMP-2/ZA (n ¼ 11) groups were tested. Comparison was also made to contralateral, intact tibiae with the caveat that these bones did not undergo a fracture procedure.
Nf1 null fractures treated with rhBMP-2 did not show equivalent strength (load to failure) to intact contralateral tibiae at 3 weeks (Fig. 3B) . In contrast, rhBMP-2/ZA co-treatment not only showed increased strength compared to rhBMP-2 alone (p < 0.01) but also was not significantly different from the contralateral leg. Other biomechanical measures showed a decrease in stiffness in the rhBMP-2 treated groups that correlated with the BV/TV values (Fig. 3C ) and increased energy absorption with rhBMP-2/ZA (Fig. 3D) . (Fig. 4A) . 9, 10 Fibrosis and cartilage were analyzed quantitatively on histological sections stained with Picrosirius Red and Alcian Blue. Both ZA-treated groups showed the lowest amounts of fibrous tissue (<5%, Fig. 4B ). Compared to BMP-2 treatment, the BMP-2/ZA specimens showed a 76% reduction in fibrous tissue (p ¼ 0.068).
Residual cartilaginous tissue was also measured, although at the 3 week time point the majority of samples had little or no remaining cartilage. The rhBMP-2 and rhBMP-2/ZA treatments showed the least cartilage at this time point (Fig. 4C) .
DISCUSSION
Tibial pseudarthrosis is a challenging orthopedic situation that is recalcitrant to many conventional approaches. The majority of surgeons recognize the anabolic deficiency that is associated with NF1 bone repair, thus to date the majority of interventions have focused on using autograft and/or rhBMP to enhance bone formation. This is consistent with preclinical models showing that NF1 is important for osteoblastic differentiation. 21, 22 However, anabolic therapies fail to target the excess osteoclastic resorption and proliferation of fibrous tissue that can be problematic in pseudarthrosis management. This may underlie the clinical failures of anabolic interventions; in a cohort that contained both NF1 and non-NF1 pseudarthroses, rhBMP-2 was less effective in treating the NF1 nonunions. 11 The concept of co-treatment using an anti-resorptive agent is one that is increasingly appreciated in the orthopedic field. 18 Potent bisphosphonates such as Pamidronate and Zoledronic Acid bind with high affinity to bone sites, and preferentially bind to areas of bone turnover. We hypothesized that this would make them ideal for use in combination with rhBMP-2 in the Nf1 null model, after showing benefits in the Nf1 +/À fracture model. 16 Indeed, in this study, we found maximum bone volume as well as improved mechanical strength with the combination treatment.
Additionally, the data showed a trend for ZA treatment to reduce fibrosis. The mechanism for this is unclear, however several hypotheses can be generated. Firstly, the anti-resorptive effects could inhibit the growth of fibrous tissue similar to the effects of ZA on osteolytic lesions. 23 Alternatively, ZA could be concentrated at the fracture site and taken up by fibrous Nf1 null cells and affect their proliferation and viability. It is also possible that a combination of both mechanisms could act, as suggested by a study where zoledronic acid inhibits tumor growth in mice with defective osteoclasts. 24 In the context of clinical surgery the majority of this tissue is actively resected. However, we speculate that bisphosphonate treatment could still yield benefits to prevent the proliferation and/or regrowth of any residual hamartoma tissue.
While these data strongly support the use of rhBMP-2/ZA as an effective treatment for NF1 pseudarthrosis, the study interpretations are limited as a preclinical model. Murine tibial fracture models feature robust healing compared to humans. In a separate Nf1 null fractures study with an 8 week end point, a significant proportion of untreated fractures were able to unite between 3 and 8 weeks (data not shown). This is an intrinsic limitation of murine models, however recapitulating the biology of Nf1 inactivation and the relative consistency of the fractures compared to the natural variation seen in clinical pseudarthroses nevertheless make it an appealing system.
In conclusion, these data support the concept that rhBMP-2/ZA can increase bone formation and union rates in an Nf1 null fracture model analogous to NF1 pseudarthrosis. In addition, ZA co-treatment was found to reduce fibrosis at the fracture site, a complication that is potentially aggravated by rhBMP-2 treatment alone. Further randomized control trials will be required to validate these data in a clinical setting. 
